Sodium iodide symporter and the radioiodine treatment of thyroid carcinoma

Nuclear Medicine and Molecular Imaging

Volumn 44, Issue 1, 2010, Pages 4-14

  Chung, June Key ^a   Youn, Hye Won ^a   Kang, Joo Hyun ^b   Lee, Ho Young ^a   Kang, Keon Wook ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Korea Institute of Radiation and Medical Science   (South Korea)

Author keywords

Gene therapy; I 131; Sodium iodide symporter (NIS); Thyroid cancer

Indexed keywords

ADENOVIRUS VECTOR; ALITRETINOIN; ARYLBUTYRIC ACID DERIVATIVE; B RAF KINASE; DEPSIPEPTIDE; DNA; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; IODINE 131; ISOTRETINOIN; LENTIVIRUS VECTOR; PENDRIN; PHENYLACETIC ACID; PROTEIN P53; RADIOACTIVE IODINE; RETINOIC ACID; RETINOIC ACID DERIVATIVE; RETINOIC ACID RECEPTOR; RHENIUM 188; ROSIGLITAZONE; SODIUM IODIDE SYMPORTER; TELOMERASE REVERSE TRANSCRIPTASE; THYROGLOBULIN; THYROID HORMONE; THYROID PEROXIDASE; THYROID TRANSCRIPTION FACTOR 1; TRICHOSTATIN A; TROGLITAZONE; UNINDEXED DRUG; VALPROIC ACID;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; BONE METASTASIS; CANCER GENE THERAPY; CANCER INHIBITION; DRUG DNA BINDING; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; GENE EXPRESSION REGULATION; GENETIC CODE; GENETIC IDENTIFICATION; HUMAN; LUNG METASTASIS; MOLECULAR CLONING; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; POINT MUTATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REVIEW; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SKIN TOXICITY; THYROID CARCINOMA; TUMOR DIFFERENTIATION; VIRAL GENE DELIVERY SYSTEM;

EID: 79952736015     PISSN: 18693474     EISSN: 18693482     Source Type: Journal    
DOI: 10.1007/s13139-009-0016-1     Document Type: Review

References (68)

1. Chung JK (2002) Sodium iodide symporter: its role in nuclear medicine. J Nucl Med 43:1188-1200.
2. Dai G, Levy O, Carrasco N (1996) Cloning and characterization of the thyroid iodide transporter. Nature 379:458-460.
3. Ministry of health and welfare (2002) Annual report of the Korea central cancer registry, 2003
4. Fernandes JK, Day TA, Richardson MS, Sharma AK (2005) Overview of the management of differentiated thyroid cancer. Curr Treat Options Oncol 6:47-57.
5. Bernier MO, Leenhardt L, Hoang C, Aurengo A, Mary JY, Menegaux F et al (2001) Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab 86:1568-1573.
6. Stojadinovic A, Shoup M, Ghossein RA, Nissan A, Brennan MF, Shah JP et al (2002) The role of operations for distant metastatic well-differentiated thyroid carcinoma. Surgery 131:636-643.
7. Shoup M, Stojadinovic A, Nissan A, Ghossein RA, Frredman S, Brennan MF et al (2003) Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg 197:191-197.
8. Hedinger C, Williams ED, Sobin LH et al (1988) Histological typing of thyroid tumours. World Health Organization International Histological Classification of Tumours. Springer Verlag, Berlin.
9. Chung JK, Kang JH (2004) Translational research using the sodium/iodide symporter in imaging and therapy. Eur J Nucl Med Mol Imaging 31:799-802.
10. 131I whole-body scan. J Nucl Med 40:986-992.
11. 131I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84:2291-2302.
12. Hooft L, Hoekstra OS, Deville W, Lips P, Tulder GJ, Boers M et al (2001) Diagnostic accuracy of F-18 fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. J Clin Endocrinol Metab 86:3779-3786.
13. Min JJ, Chung JK, Lee YJ, Jeong JM, Lee DS, Jang JJ et al (2001) Relationship between expression of the sodium/iodide symporter and I-131 uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med 28:639-645.
14. Xing M (2007) BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742-762.
15. Riesco-Eizaguirre G, Gutiérrez-Martínez P, García-Cabezas MA, Nistal M, Santisteban P (2006) The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/Itargeting to the membrane. Endocr Relat Cancer 13:257-269.
16. Romei C, Ciampi R, Faviana P, Agate L, Molinaro E, Bottici Vet al (2008) BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr Relat Cancer 15:511-520.
17. Puppin C, Arturi F, Ferretti E, Russo D, Sacco R, Tell G et al (2004) Transcriptional regulation of human sodium/iodide symporter gene: a role for redox factor-1. Endocrinology 145:1290-1293.
18. De Felice M, Di Lauro R (2004) Thyroid development and its disorders: genetics and molecular mechanisms. Endocrine Reviews 25:722-746.
19. Taki K, Kogai T, Kanamoto Y, Hershman JM, Brent GA (2002) A thyroid-specific far-upstream enhancer in the human sodium/iodide symporter gene requires Pax-8 binding and cyclic adenosine 3', 5'-monophosphate response element-like sequence binding proteins for full activity and is differentially regulated in normal and thyroid cancer cells. Mol Endocrinol 16:2266-2282.
20. Tell G, Pellizzari L, Pucillo C, Puglisi F, Cesselli D, Kelley MR et al (2000) TSH controls Ref-1 nuclear translocation in thyroid cells. J Mol Endocrinol 24:383-390.
21. Tell G, Pellizzari L, Cimarosti D, Pucillo C, Damante G (1998) Ref-1 controls pax-8 DNA-binding activity. Biochem Biophys Res Commun 252:178-183.
22. Ohmori M, Endo T, Harii N, Onaya T (1998) A novel thyroid transcription factor is essential for thyrotropin-induced upregulation of Na+/I-symporter gene expression. Mol Endocrinol 12:727-736.
23. Chun JT, Di Dato V, D'Andrea B, Zannini M, Di Lauro R (2004) The CRE-like element inside the 50-upstream region of the rat sodium/iodide symporter gene interacts with diverse classes of b-Zip molecules that regulate transcriptional activities through strong synergy with Pax-8. Mol Endocrinol 18:2817-2829.
24. Haugen BR (2004) Redifferentiation therapy in advanced thyroid cancer. Curr Drug Targets Immune Endor Metabol Disord 4:175-180.
25. Camacho LH, Olson J, Tong WP, Young CW, Spriggs DR, Malkin MG (2007) Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest New Drugs 25:131-138.
26. Coelho SM, De Carvalho DP, Vaisman M (2007) New Perspective on the treatment of differentiated thyroid cancer. Arq Bras Endocrinol Metabol 51:612-624.
27. Kogai T, Taki K, Brent GA (2006) Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer 13:797-826.
28. Marcus M, Coulton (2000) Fat-soluble vitamins A, K, E. In: Hadman JG, Limbird LE, Gilman AG (eds) Goodman and Gilmamn's the pharmacologic basis of therapeutics. Mc Graw Hill, pp 1773-1792.
29. Schmutzler C, Winzer R, Meissner-Weigl J, Kohrle J (1997) Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 240:832-838.
30. Park JW, Zarnegar R, Kanauchi H, Wong MG, Hyun WC, Ginzinger DG et al (2005) Troglitazone, the peroxisome proliferatoractivated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid 15:222-231.
31. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T (2001) Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 86:2170-2177.
32. Kitazono M, Robey R, Zhan Z, Sarlis NJ, Skarulis MC, Aikou T et al (2001) Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 86:3430-3435.
33. Akagi T, Luong QT, Gui D, Said J, Selektar J, Yung A et al (2008) Induction of sodium iodide symporter gene and molecular characterisation of HNF3 beta/FoxA2, TTF-1 and C/EBP beta in thyroid carcinoma cells. Br J Cancer 99:781-788.
34. Furuya F, Shimura H, Suzuki H, Taki K, Ohta K, Haraguchi K et al (2004) Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 145:2865-2875.
35. Fortunati N, Catalano MG, Arena K, Brignardello E, Piovesan A, Boccuzzi G (2004) Valproic acid induces the expression of the NaC/I-symporter and iodine uptake in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 89:1006-1009.
36. Venkataraman GM, Yatin M, Ain KB (1998) Cloning of the human sodium-iodide symporter promoter and characterization in a differentiated human thyroid cell line, KAT-50. Thyroid 8:63-69.
37. Kogai T, Curcio F, Hyman S, Cornford EM, Brent GA, Hershman JM (2000) Induction of follicle formation in long-term cultured normal human thyroid cells treated with thyrotropin stimulates iodide uptake but not sodium/iodide symporter messenger RNA and protein expression. J Endocrinol 167:125-135.
38. Dohan O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M et al (2003) The sodium/iodide symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 24:48-77.
39. De la Vieja A, Ginter CS, Carrasco N (2005) Molecular analysis of a congenital iodide transport defect: G543E impairs maturation and trafficking of the Na+/I-symporter. Mol Endocrinol 19:2847-2858.
40. Kurebayashi J, Tanaka K, Otsuki T, Moriya T, Kunisue H, Uno M et al (2000) All-trans retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. J Clin Endocrinol Metab 85:2889-2896.
41. Simon D, Koehrle J, Reiners C, Boerner AR, Schmutzler C, Mainz K et al (1998) Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg 22:569-574.
42. Gruenwald F, Menzel C, Bender H, Palmedo H, Otte R et al (1998) Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 39:1903-1906.
43. Gruenwald F, Pakos E, Bender H, Menzel C, Otte R, Palmedo H et al (1998) Redifferentiation therapy with retinoic acid in follicular thyroid cancer. J Nucl Med 39:1555-1558.
44. Haberkorn U, Henze M, Altmann A, Jiang S, Morr I, Mahmut M et al (2001) Transfer of the human NaI symporter gene enhances iodide uptake in hepatoma cells. J Nucl Med 42:317-325.
45. Nakamoto Y, Saga T, Misaki T, Kobayashi H, Sato N, Ishimori T et al (2000) Establishment and characterization of a breast cancer cell line expressing Na+/I-symporters for radioiodide concentrator gene therapy. J Nucl Med 41:1898-1904.
46. Boland A, Ricard M, Opolon P, Bidart JM, Yeh P, Filetti S et al (2000) Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res 60:3484-3492.
47. Spitzweg C, Dietz AB, O'Connor MK, Bergert ER, Tindall DJ, Young CY et al (2001) In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther 8:1524-1531.
48. Schipper ML, Weber A, Béhé M, Göke R, Joba W, Schmidt H et al (2003) Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumor cells. Cancer Res 63:1333-1338.
49. Kang JH, Chung JK, Lee YJ, Shin JH, Jeong JM, Lee DS et al (2004) Establishment of a human hepatocellular carcinoma cell line highly expressing sodium iodide symporter for radionuclide gene therapy. J Nucl Med 45:1571-1576.
50. Scholz IV, Cengic N, Baker CH, Harrington KJ, Maletz K, Bergert ER et al (2005) Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer. Gene Ther 12:272-280.
51. Petrich T, Quintanilla-Martinez L, Korkmaz Z, Samson E, Helmeke HJ, Meyer GJ et al (2006) Effective cancer therapy with the alpha-particle emitter [211At]astatine in a mouse model of genetically modified sodium/iodide symporter-expressing tumors. Clin Cancer Res 12:1342-1348.
52. Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC (2006) Adenovirus-mediated and targeted expression of the sodium-iodide symporter permits in vivo radioiodide imaging and therapy of pancreatic tumors. Hum Gene Ther 17:661-668.
53. Kim HJ, Jeon YH, Kang JH, Lee YJ, Kim KI, Chung HK et al (2007) In vivo long-term imaging and radioiodine therapy by sodium iodide symporter gene expression using a lentiviral system containing ubiquitin C promoter. Cancer Biol Ther 6:1130-1135.
54. Dingli D, Diaz RM, Bergert ER, O'Connor MK, Morris JC, Russell SJ (2003) Genetically targeted radiotherapy for multiple myeloma. Blood 102:489-496.
55. La Perle KM, Blomme EA, Capen CC, Jhiang SM (2003) Effect of exogenous human sodium iodide symporter expression on growth of MATLyLu cells. Thyroid 13:133-140.
56. Groot-Wassink T, Aboagye EO, Glaser M, Lemoine NR, Vassaux G (2002) Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum Gene Ther 13:1723-1735.
57. Lee YJ, Chung JK, Shin JH, Kang JH, Jeong JM, Lee DS et al (2004) In vitro and in vivo properties of a human anaplastic thyroid carcinoma cell line transfected with the sodium iodide symporter gene. Thyroid 14:889-895.
58. Snade JV, Massart C, Beauwens R, Schoutens A, Costagliola S, Dumont JE et al (2003) Anion selectivity by the sodium iodide symporter. Endocrinology 144:247-252.
59. Boland A, Magnon C, Filetti S, Bidart JM, Schlumberger M, Yeh P et al (2002) Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector-mediated gene transfers. Thyroid 12:19-26.
60. Furuya F, Shimura H, Miyazaki A, Taki K, Ohta K, Haraguchi K et al (2004) Adenovirus-mediated transfer of thyroid transcription factor-1 induces radioiodide organification and retention in thyroid cancer cells. Endocrinology 145:5397-5405.
61. Dadachova E, Carrasco N (2004) The Na/I symporter (NIS): imaging and therapeutic applications. Semin Nucl Med 34:23-31.
62. McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM et al (1998) Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 25:1341-1351.
63. Willhauck MJ, Samani BR, Gildehaus FJ, Wolf I, Senekowitsch-Schmidtke R, Stark HJ et al (2007) Application of rhenium-188 as an alternative radionuclide for treatment of prostate cancer after tumor-specific sodium iodide symporter gene expression. J Clin Endocrinol Metab 92:4451-4458.
64. Willhauck MJ, Samani BR, Wolf I, Senekowitsch-Schmidtke R, Stark HJ, Meyer GJ et al (2008) The potential of 211astatine for NIS-mediated radionuclide therapy in prostate cancer. Eur J Nucl Med Mol Imaging 35:1272-1281.
65. Spitzweg C, O'Connor MK, Bergert ER, Tindall DJ, Young CY, Morris JC (2000) Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res 60:6526-6530.
66. Jin YN, Chung HK, Kang JH, Lee YJ, Kimm KI, Kim YJ et al (2008) Radioiodine gene therapy of hepatocellular carcinoma targeted human alpha fetoprotein. Cancer Biother Radiopharm 23:551-560.
67. Willhauck MJ, Sharif Samani BR, Klutz K, Cengic N, Wolf I, Mohr L et al (2008) Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma. Gene Ther 15:214-223.
68. Kim SH, Chung HK, Kang JH, Kim KI, Jeon YH, Jin YN et al (2008) Tumor-targeted radionuclide imaging and therapy based on human sodium iodide symporter gene driven by a modified telomerase reverse transcriptase promoter. Hum Gene Ther 19:951-957.